"Russian COVID-19 Vaccine Shows Same Level of Effectiveness Across All Age Groups"

[Asia Economy Reporter Hyunseok Yoo] Claims have emerged that the Russian-made COVID-19 vaccine 'Sputnik V' shows the same level of effectiveness across all age groups.

On the 13th (local time), according to foreign media, Alexander Gintsburg, director of the Gamaleya National Research Center for Epidemiology and Microbiology under the Russian Ministry of Health, made this claim in an interview with the famous Russian YouTube channel 'Solovyov Live'.

This center is the research institute that developed the Sputnik V vaccine. Gintsburg is the director.

Director Gintsburg explained, "Initially, there were suspicions that the vaccine might be less effective in people over 60 years old," adding, "Because the immune system in the elderly is less active, they might produce a somewhat weaker immune response." He continued, "However, that did not happen," stating that the Sputnik V vaccine works well even for the elderly.

Director Gintsburg also claimed that the effectiveness of the Sputnik V vaccine could last for 2 years or more. Along with this, he emphasized, "I believe that about 60 to 70% of Russians will receive COVID-19 vaccinations by November this year."

The Sputnik V vaccine was first approved by Russia in August last year, making it the world's first. However, unlike the usual vaccine development process, it was approved based only on Phase 1 and 2 results before Phase 3 clinical trials. This led to controversy regarding its efficacy and safety.

Then, earlier last month, the Phase 3 results showing a preventive efficacy of 91.6% were published in the world-renowned medical journal 'The Lancet', leading to a more positive evaluation.

This content was produced with the assistance of AI translation services.